Caglar Gamze Sinem, Asimakopoulos Byron, Nikolettos Nikos, Diedrich Klaus, Al-Hasani Safaa
Department of Obstetrics and Gynecology, Medical University, Lubeck, Germany.
Reprod Biomed Online. 2005 Jun;10(6):774-85. doi: 10.1016/s1472-6483(10)61123-6.
The advent of recombinant gonadotrophins brought significant changes in fertility therapy. Treatment options with recombinant gonadotrophins add more to knowledge on folliculogenesis and ovarian steroidogenesis. Over a decade, recombinant LH (rLH) has been used for clinical trials, and the amount of peripheral LH that is necessary for optimal follicular growth, oocyte maturation, subsequent embryo development and assisted reproduction outcome during ovulation induction can now be better evaluated. This review evaluates the effect of rLH supplementation on ovarian stimulation and assisted reproduction outcome. The studies conducted with rLH supplementation in ovarian stimulation in different groups of patients and in cases of controlled ovarian stimulation are clearly discussed in this review.
重组促性腺激素的出现给生育治疗带来了重大变革。使用重组促性腺激素的治疗方案为卵泡发生和卵巢类固醇生成的知识增添了更多内容。十多年来，重组促黄体生成素（rLH）一直用于临床试验，现在可以更好地评估在促排卵过程中，实现最佳卵泡生长、卵母细胞成熟、后续胚胎发育及辅助生殖结局所需的外周促黄体生成素量。本综述评估了补充rLH对卵巢刺激及辅助生殖结局的影响。本综述清晰地讨论了在不同患者群体的卵巢刺激及控制性卵巢刺激病例中补充rLH所进行的研究。
